Article and Video CATEGORIES
Denise has over 30 years of varying experience in the healthcare arena. In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees. She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.
Amy’s story is shared as part of the Patient Perspectives - Clinical Trials Experiences Storytelling Program
This program aims to give those diagnosed with cancer a voice to share their experiences participating in clinical trials and help others understand the importance of participating in clinical trials. To view the full playlist of videos from the Patient Perspectives - Clinical Trials Storytelling Program, please visit the full playlist for this program here.
"No Hesitation" is Amy's story.
Diagnosed with Invasive Ductal Carcinoma (Triple Negative) in the fall of 2020, Amy was asked at her diagnosis if she would be willing to participate in a clinical trial, and she immediately agreed without hesitation. She has participated in the ARTEMIS trial through MD Anderson, and a trial of Enzalutamide and Paclitaxel Before Surgery. She has also participated in mental health studies and trials specifically for people who have been through a cancer diagnosis, through Stanford Cancer Center. This study worked to help understand how your mindset might affect one's health and well-being. She continues to participate in a study called Breaking Through the Brain Fog at the University of Texas at Dallas, focusing on education, exercises, and strategies to support brain health.
Amy's story is one of success, and not hesitating to move forward with clinical trials that saved her life.
A huge thanks to our sponsors! #exelixis #lilly #merck #blueprintmedicines
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...
Recent Comments
That's…